Palvella Therapeutics Stock Performance
| PVLA Stock | 90.43 1.99 2.25% |
On a scale of 0 to 100, Palvella Therapeutics holds a performance score of 6. The company holds a Beta of 0.83, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Palvella Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Palvella Therapeutics is expected to be smaller as well. Please check Palvella Therapeutics' treynor ratio, kurtosis, relative strength index, as well as the relationship between the downside variance and day median price , to make a quick decision on whether Palvella Therapeutics' historical price patterns will revert.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Palvella Therapeutics are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Despite somewhat uncertain essential indicators, Palvella Therapeutics sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (11.81) | Five Day Return (14.90) | Year To Date Return (11.81) | Ten Year Return 420.24 | All Time Return 420.24 |
Last Split Factor 1:80 | Last Split Date 2024-04-23 |
1 | Palvella Therapeutics Q3 Earnings Snapshot | 11/11/2025 |
2 | Will Palvella Therapeutics Inc. stock beat revenue estimates - 2025 Price Targets Long-Term Investment Growth Plans - Newser | 12/04/2025 |
3 | Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN 3.9 percent Rapamycin Anhydrous Gel for the Treatment of Cu... | 12/15/2025 |
4 | Disposition of 4302 shares by Kathleen Goin of Palvella Therapeutics at 96.472 subject to Rule 16b-3 | 12/17/2025 |
5 | Palvella Therapeutics Phase 2 Success De-Risks 2026 Catalyst - Seeking Alpha | 12/23/2025 |
6 | Palvella Therapeutics Stock Price Down 4.9 percent - Heres What Happened - MarketBeat | 01/02/2026 |
| Begin Period Cash Flow | 7.3 M | |
| Free Cash Flow | -10.8 M |
Palvella Therapeutics Relative Risk vs. Return Landscape
If you would invest 7,485 in Palvella Therapeutics on October 8, 2025 and sell it today you would earn a total of 1,359 from holding Palvella Therapeutics or generate 18.16% return on investment over 90 days. Palvella Therapeutics is currently generating 0.3972% in daily expected returns and assumes 5.0331% risk (volatility on return distribution) over the 90 days horizon. In different words, 45% of stocks are less volatile than Palvella, and 92% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Palvella Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Palvella Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Palvella Therapeutics, and traders can use it to determine the average amount a Palvella Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0789
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | PVLA | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Palvella Therapeutics is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Palvella Therapeutics by adding it to a well-diversified portfolio.
Palvella Therapeutics Fundamentals Growth
Palvella Stock prices reflect investors' perceptions of the future prospects and financial health of Palvella Therapeutics, and Palvella Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Palvella Stock performance.
| Return On Equity | -3.01 | ||||
| Return On Asset | -0.48 | ||||
| Current Valuation | 1.12 B | ||||
| Shares Outstanding | 11.84 M | ||||
| Price To Book | 30.69 X | ||||
| EBITDA | (13.12 M) | ||||
| Net Income | (17.43 M) | ||||
| Total Debt | 11.94 M | ||||
| Book Value Per Share | 3.49 X | ||||
| Cash Flow From Operations | (10.84 M) | ||||
| Earnings Per Share | (2.92) X | ||||
| Market Capitalization | 1.19 B | ||||
| Total Asset | 88.23 M | ||||
| Retained Earnings | (93.73 M) | ||||
| Working Capital | 76.2 M | ||||
About Palvella Therapeutics Performance
By analyzing Palvella Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Palvella Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Palvella Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Palvella Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.18) | (0.17) | |
| Return On Capital Employed | (0.21) | (0.22) | |
| Return On Assets | (0.18) | (0.17) | |
| Return On Equity | (0.32) | (0.34) |
Things to note about Palvella Therapeutics performance evaluation
Checking the ongoing alerts about Palvella Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Palvella Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Palvella Therapeutics had very high historical volatility over the last 90 days | |
| Net Loss for the year was (17.43 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Palvella Therapeutics generates negative cash flow from operations | |
| About 75.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Palvella Therapeutics Stock Price Down 4.9 percent - Heres What Happened - MarketBeat |
- Analyzing Palvella Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Palvella Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Palvella Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Palvella Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Palvella Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Palvella Therapeutics' stock. These opinions can provide insight into Palvella Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Palvella Stock analysis
When running Palvella Therapeutics' price analysis, check to measure Palvella Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Palvella Therapeutics is operating at the current time. Most of Palvella Therapeutics' value examination focuses on studying past and present price action to predict the probability of Palvella Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Palvella Therapeutics' price. Additionally, you may evaluate how the addition of Palvella Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |